Dyadic International Inc (DYAI) stock
DYAINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.32+0.00 (+1.30%)
Close on Nov 18, 2026Market cap $11.66MP/E –Yield –
Dyadic International revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Dyadic International's revenue for the twelve months ending Sep 30, 2026 was $3.09M, down 7.6% year over year. For fiscal 2025 it was $3.09M, down 11.6% from the year before. The highest annual figure on record is $3.50M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.09M | -11.6% |
| FY2024 | Dec 31, 2024 | $3.50M | +20.6% |
| FY2023 | Dec 31, 2023 | $2.90M | -1.1% |
| FY2022 | Dec 31, 2022 | $2.93M | +21.9% |
| FY2021 | Dec 31, 2021 | $2.40M | +50.1% |
| FY2020 | Dec 31, 2020 | $1.60M | -4.7% |
| FY2019 | Dec 31, 2019 | $1.68M | +29.8% |
| FY2018 | Dec 31, 2018 | $1.30M | +70.8% |
| FY2017 | Dec 31, 2017 | $758.42K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $449.10K | -61.4% |
| Q2 FY2026 | Jun 30, 2026 | $961.14K | -0.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.11M | +182.3% |
| Q4 FY2025 | Dec 31, 2025 | $565.53K | -30.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.16M | -40.5% |
| Q2 FY2025 | Jun 30, 2025 | $966.63K | +150.5% |
| Q1 FY2025 | Mar 31, 2025 | $393.57K | +17.6% |
| Q4 FY2024 | Dec 31, 2024 | $817.38K | +19.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.96M | +393.0% |
| Q2 FY2024 | Jun 30, 2024 | $385.90K | -53.9% |
| Q1 FY2024 | Mar 31, 2024 | $334.62K | -65.8% |
| Q4 FY2023 | Dec 31, 2023 | $686.54K | -7.7% |
| Q3 FY2023 | Sep 30, 2023 | $397.06K | -54.9% |
| Q2 FY2023 | Jun 30, 2023 | $837.16K | +27.1% |
| Q1 FY2023 | Mar 31, 2023 | $978.05K | +50.8% |
| Q4 FY2022 | Dec 31, 2022 | $743.73K | +137.4% |
| Q3 FY2022 | Sep 30, 2022 | $879.60K | +26.9% |
| Q2 FY2022 | Jun 30, 2022 | $658.55K | -29.7% |
| Q1 FY2022 | Mar 31, 2022 | $648.43K | -99.9% |
| Q4 FY2021 | Dec 31, 2021 | $313.29K | -9.4% |
| Q3 FY2021 | Sep 30, 2021 | $692.93K | +66.4% |
| Q2 FY2021 | Jun 30, 2021 | $937.09K | +78.7% |
| Q1 FY2021 | Mar 31, 2021 | $460.52M | +145924.4% |
| Q4 FY2020 | Dec 31, 2020 | $345.92K | -20.1% |
| Q3 FY2020 | Sep 30, 2020 | $416.36K | -8.4% |
| Q2 FY2020 | Jun 30, 2020 | $524.27K | +34.1% |
| Q1 FY2020 | Mar 31, 2020 | $315.37K | -21.7% |
| Q4 FY2019 | Dec 31, 2019 | $433.17K | -36.9% |
| Q3 FY2019 | Sep 30, 2019 | $454.51K | +72.8% |
| Q2 FY2019 | Jun 30, 2019 | $390.87K | +142.3% |
| Q1 FY2019 | Mar 31, 2019 | $402.53K | +118.4% |
| Q4 FY2018 | Dec 31, 2018 | $686.88K | – |
| Q3 FY2018 | Sep 30, 2018 | $262.96K | – |
| Q2 FY2018 | Jun 30, 2018 | $161.29K | – |
| Q1 FY2018 | Mar 31, 2018 | $184.33K | – |
See a number that looks wrong?